Cochlear downgrades ear-nings on sluggish sales
Cochlear downgrades full-year profit expectations, citing sluggish sound processor sales Mesoblast eyes second US drug approval sooner rather than later Who’s for a bargain biotech … or three? Cochlear (ASX:COH) is banking on the rollout of new hearing …